血液学の最新論文（2018年11月リリース分）New reports on Hematology
Leukemia
- Blood Not so lost in translation: RPS15 mutations in CLL. 132(22):2317-2319 Ljungström V, Rosenquist R
- Blood Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. 132(22):2375-2388 Bretones G, Álvarez MG, Arango JR, Rodríguez D, Nadeu F, Prado MA, Valdés-Mas R, Puente DA, Paulo JA, Delgado J, Villamor N, López-Guillermo A, Finley DJ, Gygi SP, Campo E, Quesada V, López-Otín C
- Blood Mixed-phenotype acute leukemia, T/megakaryoblastic. 132(22):2418 Klairmont MM, Choi JK
- Blood A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. 132(21):2249-2259 Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V
- Blood Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. 132(21):2260-2272 de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP
- Blood Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes. 132(21):2314 Jiang W, Lee SH
- Blood Molecular monitoring in CML: how deep? How often? How should it influence therapy? 132(20):2125-2133 Shanmuganathan N, Hughes TP
- Blood miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. 132(20):2179-2182 Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM
- Blood B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia. 132(19):2107 Lebecque B, Lechevalier N
- Blood Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. 132(18):1899-1910 Qin H, Ishii K, Nguyen S, Su PP, Burk CR, Kim BH, Duncan BB, Tarun S, Shah NN, Kohler ME, Fry TJ
- Blood Donor-derived MDS/AML in families with germline GATA2 mutation. 132(18):1994-1998 Galera P, Hsu AP, Wang W, Droll S, Chen R, Schwartz JR, Klco JM, Arai S, Maese L, Zerbe C, Parta MJ, Young NS, Holland SM, Hickstein DD, Calvo KR
- Br J Haematol Highly atypical myeloblasts in acute myeloid leukaemia with myelodysplasia-related changes in a patient with short telomere syndrome. 183(4):536 Li Y, Dorfman DM
- Br J Haematol Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study. 183(4):618-628 Bager N, Juul-Dam KL, Sandahl JD, Abrahamsson J, Beverloo B, de Bont ESJM, Ha SY, Jahnukainen K, Jónsson ÓG, Kaspers GL, Kovalova Z, Lausen B, De Moerloose B, Noren-Nyström U, Palle J, Saks K, Zeller B, Kjeldsen E, Hasle H
- Br J Haematol Inherited THPO mutation, with morphology resembling chronic myeloid leukaemia. 183(3):344 Murray JW, Thakur I, Connor PP
- Br J Haematol Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). 183(3):411-420 Canaani J, Labopin M, Huang XJ, Ciceri F, Van Lint MT, Bruno B, Santarone S, Diez-Martin JL, Blaise D, Chiusolo P, Wu D, Mohty M, Nagler A
- Br J Haematol Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. 183(3):421-427 Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA
- Br J Haematol Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity. 183(3):445-456 Wu L, Amarachintha S, Xu J, Oley F Jr, Du W
- Haematologica To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia. 103(11):1756-1757 Schiffer JT, Schiffer CA
- Haematologica Older adults with acute myeloid leukemia treated with intensive chemotherapy: “old” prognostic algorithms may not apply. 103(11):1758-1759 Stone RM, Lindsley C
- Haematologica Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. 103(11):1825-1834 Fassoni AC, Baldow C, Roeder I, Glauche I
- Haematologica Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. 103(11):1835-1842 Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H; STAT study group
- Haematologica Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. 103(11):1843-1852 Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D
- Haematologica Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. 103(11):1853-1861 Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH
- Haematologica MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. 103(11):1862-1872 Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T
- Haematologica Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). 103(11):1873-1880 Nikkilä A, Raitanen J, Lohi O, Auvinen A
- Haematologica Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. 103(11):1881-1888 Solans M, Castelló A, Benavente Y, Marcos-Gragera R, Amiano P, Gracia-Lavedan E, Costas L, Robles C, Gonzalez-Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Dierssen-Sotos T, Fernández-Tardón G, Olmedo-Requena R, Gimeno E, Castaño-Vinyals G, Aragonés N, Kogevinas M, de Sanjose S, Pollán M, Casabonne D
- Haematologica Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. 103(11):1889-1898 Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R
- Haematologica The long non-coding RNA landscape in juvenile myelomonocytic leukemia. 103(11):e501-e504 Hofmans M, Lammens T, Helsmoortel HH, Bresolin S, Cavé H, Flotho C, Hasle H, van den Heuvel-Eibrink MM, Niemeyer C, Stary J, Van Roy N, Van Vlierberghe P, Philippé J, De Moerloose B
- Haematologica Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia. 103(11):e505-e509 Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP
- Haematologica Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. 103(11):e510-e513 Tien FM, Hou HA, Tang JL, Kuo YY, Chen CY, Tsai CH, Yao M, Lin CT, Li CC, Huang SY, Ko BS, Hsu SC, Wu SJ, Liu JH, Chou SC, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF
- Haematologica Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. 103(11):e514-e518 Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK
- Haematologica Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). 103(11):e519-e521 Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P
- Haematologica Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. 103(11):e522-e526 Tanaka Y, Kawazu M, Yasuda T, Tamura M, Hayakawa F, Kojima S, Ueno T, Kiyoi H, Naoe T, Mano H
- Haematologica Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. 103(11):e527-e530 Brunel AS, Wójtowicz A, Lamoth F, Spertini O, Neofytos D, Calandra T, Marchetti O, Bochud PY
- Haematologica A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. 103(11):e531-e536 Gugiatti E, Tenca C, Ravera S, Fabbi M, Ghiotto F, Mazzarello AN, Bagnara D, Reverberi D, Zarcone D, Cutrona G, Ibatici A, Ciccone E, Darzynkiewicz Z, Fais F, Bruno S
- Haematologica A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms. 103(11):e549-e552 Vinhas R, Lourenço A, Santos S, Ribeiro P, Silva M, de Sousa AB, Baptista PV, Fernandes AR
- J Clin Oncol What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia? 36(32):3183–3185 Flowers CR, Ramsey SD
- J Clin Oncol Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter. 36(32):3186–3188 Carraway HE
- J Clin Oncol Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. 36(32):3192–3202 Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQL, Davis KL, Owens DK, Goldhaber-Fiebert JD
- J Clin Oncol Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. 36(32):3203–3210 Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization
- Lancet Oncol Lomustine in older patients with acute myeloid leukaemia. 19(11):e584 Gourd E
- Leukemia Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. 32(11):2316–2325 Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA
- Leukemia New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment. 32(11):2326–2338 Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS, Kees UR
- Leukemia UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response. 32(11):2339–2351 Huiting LN, Samaha Y, Zhang GL, Roderick JE, Li B, Anderson NM, Wang YW, Wang L, Laroche F, Choi JW, Liu CT, Kelliher MA, Feng H
- Leukemia Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. 32(11):2352–2362 Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB
- Leukemia FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. 32(11):2363–2373 Hu T, Wu Q, Chong Y, Qin H, Poole CJ, van Riggelen J, Ren M, Cowell JK
- Leukemia Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. 32(11):2374–2387 Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A
- Leukemia Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. 32(11):2388-2398 Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG
- Leukemia Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene. 32(11):2498–2501 Studencka-Turski M, Maubach G, Feige MH, Naumann M
- Leukemia GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. 32(11):2502–2507 Al Seraihi AF, Rio-Machin A, Tawana K, Bödör C, Wang J, Nagano A, Heward JA, Iqbal S, Best S, Lea N, McLornan D, Kozyra EJ, Wlodarski MW, Niemeyer CM, Scott H, Hahn C, Ellison A, Tummala H, Cardoso SR, Vulliamy T, Dokal I, Butler T, Smith M, Cavenagh J, Fitzgibbon J
- Leukemia Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. 32(11):2512–2518 Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G
- N Engl J Med Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. 379(19):1873-1874 Ebert BL, Krönke J
Lymphoma
- Blood Targeting EBV-positive B- and T/NK-cell lymphomas. 132(22):2315-2316 Long HM
- Blood EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. 132(22):2351-2361 McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM
- Blood miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. 132(22):2389-2400 Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M
- Blood Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. 132(22):2401-2405 Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM
- Blood A small change makes a big difference in Hodgkin lymphoma. 132(21):2214-2215 Hutchings M
- Blood Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. 132(21):2240-2248 Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE
- Blood Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. 132(21):2273-2279 Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M
- Blood IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. 132(21):2280-2285 Wagener R, López C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hübschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, de Leval L, Nürnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wössmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Küppers R, Siebert R
- Blood Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. 132(21):2305-2309 Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, Pelletier L, Marçais A, Robe C, Fataccioli V, Haioun C, Hermine O, Gaulard P, Delarue R
- Blood Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. 132(19):2016-2025 Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP
- Blood PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. 132(19):2026-2039 Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS
- Blood Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. 132(19):2040-2052 Sud A, Thomsen H, Orlando G, Försti A, Law PJ, Broderick P, Cooke R, Hariri F, Pastinen T, Easton DF, Pharoah PDP, Dunning AM, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N, Campa D; PRACTICAL Consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS
- Blood Biology and management of primary effusion lymphoma. 132(18):1879-1888 Shimada K, Hayakawa F, Kiyoi H
- Blood How I treat breast implant-associated anaplastic large cell lymphoma. 132(18):1889-1898 Mehta-Shah N, Clemens MW, Horwitz SM
- Blood Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma. 132(18):1922-1935 Kamijo H, Miyagaki T, Shishido-Takahashi N, Nakajima R, Oka T, Suga H, Sugaya M, Sato S
- Br J Haematol Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study. 183(4):564-577 Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E
- Br J Haematol Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. 183(4):578-587 Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML
- Br J Haematol Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. 183(4):601-607 Lihua E. Budde, David Wu, Daniel B. Martin, Mary Philip, Andrei R. Shustov, Stephen D. Smith, Ted A. Gooley, Tara L. Chen, Edward N. Libby, Eric Y. Chen, Kiarash Kojouri, Alan Langerak, Jennifer E. Roden, Oliver W. Press, Ajay K. Gopal
- Br J Haematol Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis. 183(3):345 Khan UT, Racu-Amoasii I, Arumainathan A, Meswani U, Pettitt AR, Menon G
- Br J Haematol Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. 183(3):400-410 Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B
- Br J Haematol Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. 183(3):428-444 Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL
- Haematologica Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. 103(11):1899-1907 McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM
- Haematologica PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. 103(11):1908-1914 Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S
- Haematologica In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. 103(11):e537-e540 Pérez-Salvia M, Aldaba E, Vara Y, Fabre M, Ferrer C, Masdeu C, Zubia A, Sebastian ES, Otaegui D, Llinàs-Arias P, Rosselló-Tortella M, Berdasco M, Moutinho C, Setien F, Villanueva A, González-Barca E, Muncunill J, Navarro JT, Piris MA, Cossio FP, Esteller M
- Haematologica Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. 103(11):e541-e543 Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K
- Haematologica Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation. 103(11):e553-e556 Ochi Y, Hiramoto N, Yoshizato T, Ono Y, Takeda J, Shiozawa Y, Yoshida K, Kakiuchi N, Shiraishi Y, Tanaka H, Chiba K, Kazuma Y, Tabata S, Yonetani N, Uehara K, Yamashita D, Imai Y, Nagafuji K, Yamakawa M, Miyano S, Takaori-Kondo A, Ogawa S, Ishikawa T
- J Clin Oncol Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. 36(33):3307–3314 Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA
- J Clin Oncol Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. 36(33):3315–3323 Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E
- Lancet Haematol Histological transformation and secondary malignancies in follicular lymphoma. 5(11):e496-e497 Vitolo U, Chiappella A
- Lancet Haematol Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. 5(11):e520-e531 Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators
- Lancet Haematol Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. 5(11):e543-e553 Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW
- Lancet Oncol Bortezomib-based chemotherapy in mantle cell lymphoma. 19(11):1419-1421 Rule S
- Lancet Oncol Personalised approach in follicular lymphoma. 19(11):1431-1432 Luminari S
- Lancet Oncol Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study 19(11):1449-1458 Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators
- Lancet Oncol Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. 19(11):1530-1542 Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study
- Leukemia Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. 32(11):2316–2325 Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA
- Leukemia FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. 32(11):2363–2373 Hu T, Wu Q, Chong Y, Qin H, Poole CJ, van Riggelen J, Ren M, Cowell JK
- Leukemia High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. 32(11):2412-2426 Pillonel V, Juskevicius D, Ng CKY, Bodmer A, Zettl A, Jucker D, Dirnhofer S, Tzankov A
- N Engl J Med CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. 379(18):1711-1721 Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM
Myeloma
- Blood IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. 132(20):2166-2178 Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, Grigoriadis G, Tellier J, Nutt SL
- Blood Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. 132(19):2097-2100 Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T
- Br J Haematol Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations. 183(4):538-556 Swan D, Rocci A, Bradbury C, Thachil J
- Br J Haematol Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. 183(3):375-384 Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudziński M, Raźny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jażdżewska E, Sainz J, Canzian F, Campa D
- Haematologica European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. 103(11):1772-1784 Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M
- Haematologica Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. 103(11):e544-e548 Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J
- Lancet Oncol Combination therapy for first relapse of multiple myeloma. 19(11):e587 Gourd E
- Leukemia Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. 32(11):2427-2434 Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF
- Leukemia Kinase domain activation through gene rearrangement in multiple myeloma. 32(11):2435-2444 Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA
- Leukemia Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. 32(11):2459-2470 Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houlston RS
- Leukemia Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. 32(11):2471–2482 Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H
- Leukemia Ninety-minute daratumumab infusion is safe in multiple myeloma. 32(11):2495-2518 Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, Benson DM, Rosko AE, Efebera YA, Hofmeister CC
- N Engl J Med Immunotherapy Combinations in Multiple Myeloma – Known Unknowns. 379(19):1791-1795 Gormley NJ, Pazdur R
- N Engl J Med Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. 379(19):1811-1822 Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J
SCT
- Br J Haematol Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. 183(3):400-410 Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B
- J Clin Oncol Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. 36(31):3162–3171 Diorio C, Robinson PD, Ammann RA, Castagnola E, Erickson K, Esbenshade A, Fisher BT, Haeusler GM, Kuczynski S, Lehrnbecher T, Phillips R, Cabral S, Dupuis LL, Sung L
HSC
- Haematologica Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. 103(11):1806-1814 Adair JE, Chandrasekaran D, Sghia-Hughes G, Haworth KG, Woolfrey AE, Burroughs LM, Choi GY, Becker PS, Kiem HP
- J Clin Oncol High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. 36(31):3110–3119 Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators
- J Clin Oncol Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. 36(31):3162–3171 Diorio C, Robinson PD, Ammann RA, Castagnola E, Erickson K, Esbenshade A, Fisher BT, Haeusler GM, Kuczynski S, Lehrnbecher T, Phillips R, Cabral S, Dupuis LL, Sung L
Anemia
- Blood Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia. 132(20):2205-2208 Vlachos A, Rosenberg PS, Atsidaftos E, Kang J, Onel K, Sharaf RN, Alter BP, Lipton JM
- Haematologica Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. 103(11):1806-1814 Adair JE, Chandrasekaran D, Sghia-Hughes G, Haworth KG, Woolfrey AE, Burroughs LM, Choi GY, Becker PS, Kiem HP
Bone marrow failure
- このキーワードに関連した論文はありません